Talk:GLP-1 receptor agonist

	This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects:
Pharmacology Mid‑importance This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks. Mid This article has been rated as Mid-importance on the project's importance scale.

Requested move 5 November 2023

The following is a closed discussion of a requested move. Please do not modify it. Subsequent comments should be made in a new section on the talk page. Editors desiring to contest the closing decision should consider a move review after discussing it on the closer's talk page. No further edits should be made to this discussion.

The result of the move request was: Moved (closed by non-admin page mover) BegbertBiggs (talk) 15:15, 12 November 2023 (UTC)[reply]

---

Glucagon-like peptide-1 receptor agonist → GLP-1 receptor agonist – The majority of scholarly sources don't seem to be spelling out the name, per Google Scholar results since 2019:

• GLP-1 agonist: 4,000
• GLP-1 receptor agonist: 10,600
• "Glucagon-like peptide-1 receptor agonist" 9700
• "Glucagon-like peptide-1 agonist": 900

Thus, I think it meets WP:ACROTITLE for using an acronym in the title, and I also think that GLP-1 is more recognizable to our readership than the spelled out name. I would also support "GLP-1 agonist" if that's what the consensus goes for, as this term is used in many sources aimed at a popular audience (see Google search or news results). (t · c) buidhe 04:30, 5 November 2023 (UTC)[reply]

Support - following Wikipedia:ACROTITLE . But just a comment that related pages are not moved yet. See Glucagon-like peptide-1 and Glucagon-like peptide-1 receptor Hongsy (talk) 02:41, 9 November 2023 (UTC)[reply]

It's not necessarily the case that they need or should be the same, after all we have Central Intelligence Agency but CIA controversies. I think the other articles need evaluating on their own merits especially since they are of more scientific /less popular interest than this article. (t · c) buidhe 02:52, 9 November 2023 (UTC)[reply]

The discussion above is closed. Please do not modify it. Subsequent comments should be made on the appropriate discussion page. No further edits should be made to this discussion.

Wiki Education assignment: Molecular Neuropharmacology

This article was the subject of a Wiki Education Foundation-supported course assignment, between 25 August 2025 and 8 December 2025. Further details are available on the course page. Student editor(s): ScienceLady13 (article contribs).

— Assignment last updated by Xx684xx (talk) 14:50, 17 September 2025 (UTC)[reply]

Proposed addition to Obesity section (COI edit request) - December 11, 2025

The user below has a request that an edit be made to GLP-1 receptor agonist. That user has an actual or apparent conflict of interest. The requested edits backlog is very high. Please be extremely patient. There are currently 316 requests waiting for review. Please read the instructions for the parameters used by this template for accepting and declining them, and review the request below and make the edit if it is well sourced, neutral, and follows other Wikipedia guidelines and policies.

Proposed addition to Obesity section (COI edit request)

Hello, I have a conflict of interest as an employee of Truveta and therefore will not edit the article directly. I am requesting an independent editor’s review.

I propose adding a brief summary of a 2025 peer-reviewed cohort study examining real-world patterns of discontinuation and reinitiation of GLP-1 receptor agonists among U.S. adults with overweight or obesity. The study does not evaluate Truveta itself; it uses electronic health record data from multiple U.S. health systems that contribute data to Truveta. The findings provide updated evidence relevant to long-term treatment patterns described in the Obesity subsection.

Proposed sentence:

A 2025 cohort study using electronic health record data from multiple U.S. health systems contributing data to Truveta found that adults with overweight or obesity frequently discontinued dual-labeled GLP-1 receptor agonists and later reinitiated therapy, reporting substantial variability in real-world treatment persistence and medication cycling.^[1]

I suggest placing this sentence in the "Obesity" subsection, immediately after the existing sentence noting that many individuals regain weight after discontinuing GLP-1 medications.

Thank you for your consideration.

1. Rodriguez, Patricia J.; Zhang, Vincent; Gratzl, Samuel (2025-01-31). "Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity". JAMA Network Open. 8 (1): e2457349. doi:10.1001/jamanetworkopen.2024.57349. PMC 11786232. PMID 39888616.

Lyolek25 (talk) 21:47, 11 December 2025 (UTC)[reply]